(Q54687747)

2 June 2018

title

Combined detection of Her2/neu gene amplification and protein overexpression in effusions from patients with breast and ovarian cancer. (English)

1 reference

2 June 2018

1 reference

Birgitta Schlüter

1

1 reference

2 June 2018

Roswitha Gerhards

series ordinal

2

1 reference

2 June 2018

Dirk Strumberg

series ordinal

3

1 reference

2 June 2018

Rudolf Voigtmann

series ordinal

4

1 reference

2 June 2018

publication date

9 March 2010

1 reference

2 June 2018

Journal of Cancer Research and Clinical Oncology

published in

1 reference

2 June 2018

volume

136

1 reference

2 June 2018

issue

9

1 reference

2 June 2018

page(s)

1389-1400

1 reference

2 June 2018

https://scigraph.springernature.com/pub.10.1007/s00432-010-0790-2

exact match

0 references

cites work

Multicolor-FICTION: expanding the possibilities of combined morphologic, immunophenotypic, and genetic single cell analyses

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS00432-010-0790-2

Telomere length assessment in human archival tissues: combined telomere fluorescence in situ hybridization and immunostaining

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS00432-010-0790-2

Neu-protein overexpression in breast cancer. Association with comedo-type ductal carcinoma in situ and limited prognostic value in stage II breast cancer

21 January 2018

1 reference

12 December 2020

The influence of polysomy 17 on HER2 gene and protein expression in adenocarcinoma of the breast: a fluorescent in situ hybridization, immunohistochemical, and isotopic mRNA in situ hybridization study

1 reference

12 December 2020

The effects of antibody clone and pretreatment method on the results of HER2 immunostaining in cytologic samples of metastatic breast cancer: A query and a review of the literature

1 reference

12 December 2020

Chromogenic in situ hybridization in tumor pathology

1 reference

12 December 2020

Her-2/neu expression in node-negative breast cancer: direct tissue quantitation by computerized image analysis and association of overexpression with increased risk of recurrent disease.

1 reference

12 December 2020

Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer

1 reference

12 December 2020

When is a tumor marker ready for prime time? A case study of c-erbB-2 as a predictive factor in breast cancer

1 reference

12 December 2020

Gene amplification and tumor progression

1 reference

12 December 2020

Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer

1 reference

12 December 2020

Simultaneous fluorescence immunophenotyping and interphase cytogenetics: a contribution to the characterization of tumor cells

1 reference

12 December 2020

HER2 assessment by immunohistochemical analysis and fluorescence in situ hybridization: comparison of HercepTest and PathVysion commercial assays

1 reference

12 December 2020

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

1 reference

12 December 2020

HER-2 (c-erbB-2) test update: present status and problems

1 reference

12 December 2020

Relevance of p185 HER-2/neu oncoprotein quantification in human primary breast carcinoma

1 reference

12 December 2020

Induction of topoisomerase II activity after ErbB2 activation is associated with a differential response to breast cancer chemotherapy.

1 reference

12 December 2020

c-myc, c-erbB-2, and Ki-67 expression in normal breast tissue and in invasive and noninvasive breast carcinoma

1 reference

12 December 2020

Calibration of immunohistochemistry for assessment of HER2 in breast cancer: results of the French multicentre GEFPICS study

1 reference

12 December 2020

Role of different immunostaining patterns in HercepTest interpretation and criteria for gene amplification as determined by fluorescence in situ hybridization

1 reference

12 December 2020

Immunohistochemical distribution of c-erbB-2 in infiltrating and in situ breast cancer

1 reference

12 December 2020

Chromosome 17 aneusomy is associated with poor prognostic factors in invasive breast carcinoma

1 reference

12 December 2020

Role of chromogenic in situ hybridization (CISH) in the evaluation of HER2 status in breast carcinoma: comparison with immunohistochemistry and FISH

1 reference

12 December 2020

Direct detection of herceptin/trastuzumab binding on breast tissue sections

1 reference

12 December 2020

Aneusomy 17 in breast cancer: its role in HER-2/neu protein expression and implication for clinical assessment of HER-2/neu status

1 reference

12 December 2020

Clinicopathologic analysis of breast carcinoma with chromosomal aneusomy detected by fluorescence in situ hybridization

1 reference

12 December 2020

Polysomy 17 in HER-2/neu Status Elaboration in Breast Cancer: Effect on Daily Practice

1 reference

12 December 2020

Chromosome analysis of 97 primary breast carcinomas: identification of eight karyotypic subgroups

1 reference

12 December 2020

Combined Whole-Mount in Situ Hybridization and Immunohistochemistry in Avian Embryos

1 reference

12 December 2020

Numerical aberrations of chromosome 17 in interphase cell nuclei of breast carcinoma cells: lack of correlation with abnormal expression of p53, neu and nm23 protein

1 reference

12 December 2020

Predicting the HER2 status of breast cancer from basic histopathology data: an analysis of 1500 breast cancers as part of the HER2000 International Study

1 reference

12 December 2020

Localization of the human erbB-2 gene on normal and rearranged chromosomes 17 to bands q12-21.32.

1 reference

12 December 2020

PGDS, a novel technique combining chromogenic in situ hybridization and immunohistochemistry for the assessment of ErbB2 (HER2/neu) status in breast cancer

1 reference

12 December 2020

Targeted therapy in breast cancer: the HER-2/neu gene and protein

1 reference

12 December 2020

Reliability and discriminant validity of HER2 gene quantification and chromosome 17 aneusomy analysis by real-time PCR in primary breast cancer

1 reference

12 December 2020

Determination of HER-2 status and chromosome 17 polysomy in breast carcinomas comparing HercepTest and PathVysion FISH assay.

1 reference

12 December 2020

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

1 reference

12 December 2020

HER-2 as a Prognostic, Predictive, and Therapeutic Target in Breast Cancer

1 reference

12 December 2020

American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer.

1 reference

12 December 2020

Immunohistochemical expression of internal and external ErbB-2 domains in invasive breast cancer

1 reference

12 December 2020

Modulation of HER2 expression by ferulic acid on human breast cancer MCF7 cells

1 reference

12 December 2020

IHC for Her2 with CBE356 antibody is a more accurate predictor of Her2 gene amplification by FISH than HercepTest in breast carcinoma

1 reference

12 December 2020

Strong HER-2/neu protein overexpression by immunohistochemistry often does not predict oncogene amplification by fluorescence in situ hybridization.

1 reference

12 December 2020

Central HER2 IHC and FISH analysis in a trastuzumab (Herceptin) phase II monotherapy study: assessment of test sensitivity and impact of chromosome 17 polysomy

1 reference

12 December 2020

Assessment of HER‐2/neu overexpression and/or gene amplification in breast carcinomas: should in situ hybridization be the method of choice?

1 reference

12 December 2020

Combined immunophenotyping and DNA in situ hybridization to study lineage involvement in patients with myelodysplastic syndromes

1 reference

12 December 2020

Simultaneous detection of HER2/neu gene amplification and protein overexpression in paraffin-embedded breast cancer

1 reference

12 December 2020

Cancer genetics, cytogenetics--defining the enemy within

1 reference

12 December 2020

HER-2/neu testing in breast carcinoma: a combined immunohistochemical and fluorescence in situ hybridization approach

1 reference

12 December 2020

Impact of polysomy 17 on HER-2/neu immunohistochemistry in breast carcinomas without HER-2/neu gene amplification

1 reference

12 December 2020

Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: a direct comparison of fluorescence in situ hybridization and immunohistochemistry

1 reference

12 December 2020

HER2 testing in patients with breast cancer: poor correlation between weak positivity by immunohistochemistry and gene amplification by fluorescence in situ hybridization

1 reference

12 December 2020

TOP2A and HER-2 gene amplification in fine needle aspirates from breast carcinomas.

1 reference

12 December 2020

Clinical evaluation of HER-2/neu protein in malignant pleural effusion-associated lung adenocarcinoma and as a tumor marker in pleural effusion diagnosis

1 reference

12 December 2020

Combined FISH and immunolabeling on paraffin-embedded tissue sections for the study of microchimerism

1 reference

12 December 2020

10.1007/S00432-010-0790-2

Identifiers

DOI

1 reference

2 June 2018

1 reference

2 June 2018